Lightship vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Lightship is a clinical research organization (CRO) specializing in decentralized and hybrid clinical trial design, combining in-clinic visits, at-home appointments, mobile research units, and digital health tools to improve participant access and.
About
Lightship is a clinical research organization (CRO) founded with the mission of reimagining how clinical trials are designed and conducted to dramatically improve participant access and health equity. Traditional clinical research requires participants to travel to major academic medical centers or specialized research sites for frequent, often burdensome in-clinic visits — a model that systematically excludes working adults, rural populations, elderly patients, and underrepresented communities. Lightship designs and executes studies using a spectrum of participation modalities: traditional in-clinic visits, at-home appointments with study nurses who travel to participants, mobile research units that bring clinical procedures to community locations, and digital health tools that enable remote data collection between visits.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.